Printer Friendly


 -- Company Develops Technologies to Reduce
 Likelihood of Organ Rejection --
 CAMBRIDGE, England, Sept. 28 /PRNewswire/ -- At the Second International Congress on Xenotransplantation here, DNX Corporation (NASDAQ: DNXX) today announced it has recently developed transgenic animals which possess critical elements that may enable the transplantation of animal organs to humans with a reduced risk of organ rejection.
 "With the breakthrough research presented today, DNX has demonstrated that the technology exists to develop animal organs that may be less likely to suffer rejection upon transplantation to humans," said Jeffrey Platt, M.D., of Duke University Medical Center, a pioneer and leading authority of xenograft research, as well as a consultant to several companies and agencies engaged in supporting xenotransplantation research, including DNX. "These results bring the prospect of successful xenotransplantation a major step closer to reality."
 One of the major barriers to successful xenotransplantation, or animal to human organ transplantation, has been hyperacute rejection of the transplanted organ mediated by complement, certain inflammatory proteins of the immune system. This results in the nearly immediate destruction of the organ within minutes to hours. Normally, the complement system is held in check by complement inhibition factors.
 "To use transgenic animal technology optimally for the control of complement mediated injury to transplanted organs, a series of challenges need to be met. The first is to get an expression of a human complement inhibition gene in transgenic pigs. This has been accomplished by DNX as well as others. A second is to achieve expression of a combination of more than one such human complement inhibition factor to obtain more extensive protection against the various inflammatory proteins of the complement cascade. This expression has now been demonstrated by DNX in both transgenic mice and pigs. A third challenge is to demonstrate that the presence of these complement inhibition factors in an animal organ will actually block human complement. The evidence to date indicates that this has been achieved in DNX's transgenic mice. The ultimate goal is to achieve successful transplantation with transgenic pig organs bearing human complements inhibition factors. Personally speaking, after years of thinking and talking about such a transgenic animal approach, with DNX's success in both transgenic mice and pigs, meeting thus ultimate challenge finally seems possible," said Dr. Platt, a member of the Congress's International Advisory Board.
 At the Xenotransplantation Conference today, DNX scientists presented data showing that in a model of what would occur upon xenotransplantation of animal organs to human, DNX successfully inhibited complement in transgenic mouse hearts exposed to human plasma. Employing DNA sequences similar to those used to achieved the foregoing successful result in transgenic mice, DNX had developed transgenic pigs expressing multiple human complement inhibition genes.
 "If we are able to maintain our current rate of progress, DNX should be posed to begin human clinical testing of transgenic pig organs in three to five years," according to John Logan, Ph.D., DNX's vice president of research and preclinical development. "We believe that organs from our transgenic pigs will less likely to suffer complement mediated injury and rejection," he said. DNX plans to repeat the experiment modeling human transplantation, this time using transgenic pig hearts when appropriate second generation pigs, bred from transgenic founder animals, become available as organ donors.
 "DNX continues to make significant progress in the development of our xenotransplantation technology," said Paul Schmitt, DNX president and CEO. "DNX is among the leaders in a wave of advancements in xenotransplantation. We are the first company to show not just the existence, but the activity, of multiple human complement inhibition genes in a transgenic animal -- one of the biggest hurdles to developing animal organs for human transplantation."
 Xenotransplantation is increasingly viewed as the most promising potential solution to the chronic shortage of transplantable human organs. It is estimated that if safe and effective xenotransplantation with transgenic swine organs can be achieved, more than 100,000 patients worldwide could receive desperately needed organs each year.
 "It is clear that the shortage of donor human organs is a major public health crisis. The problem will not be solved until xenotransplantation becomes a reality," said Randall Bollinger, M.D., Ph.D., of Duke University and recent past president of the United Network for Organ Sharing (UNOS), the federally chartered organization charged with achieving the distribution of organs in the United States. "Ultimately, the use of transgenic animal techniques will be necessary, in my opinion, to bring xenotransplantation into the clinical arena."
 The Second International Congress on Xenotransplantation, which runs from Sept. 26-29 in Cambridge, is a major international forum dedicated to educating the scientific community about advances in xenotransplantation. It is sponsored this year by the Clinical School at the University of Cambridge and endorsed by The Transplantation Society.
 DNX Corporation is a life sciences company operating through two wholly-owned subsidiaries. DNX Biotherapeutics, Inc. is a leader in the research and development of therapeutic blood substitute and organ transplantation products largely based on transgenic animal technology. Pharmakon Research International is a leading supplier of preclinicals and biological testing services to the biotechnology, pharmaceutical and chemical industries.
 -0- 9/28/93
 /CONTACT: In the United Kingdom, Steven Holtzman, president of DNX Therapeutics, DNX Corporation, 011-44-71-636-1000, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, 011-44-71-489-1441, or in New York, Paul J. Schmitt, president & CEO of DNX Corporation, 609-520-0300, or Kathryn Comba or Rhonda Chiger, both of Noonan-Russo Communications, 212-696-4455/

CO: DNX Corporation ST: New Jersey IN: MCT SU: PDT

TM -- NY004 -- 6216 09/28/93 08:04 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 28, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters